Physician profile
Daniel Mark Entwistle
NPI 1649413600
$1,486.37
in general payments reported to CMS, 2019-2025
21 companies · $111 in 2025
The $111 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $121 · 2021: $142 · 2022: $327 · 2023: $341 · 2024: $281 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $733.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $318.46 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $282.62 | 2019-2024 | Jornay Pm |
| Cranial Technologies, INC | $142.87 | 2021-2024 | Doc Band |
| Glaxosmithkline, LLC. | $142.46 | 2019-2023 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $97.86 | 2019-2022 | |
| Pfizer INC. | $79.51 | 2020-2025 | |
| Tris Pharma INC | $70.38 | 2019-2024 | Dyanavel Xr |
| Sobi, INC | $47.19 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $42.83 | 2020-2022 | |
| Neos Therapeutics, Lp | $35.59 | 2022 | |
| Collegium Pharmaceutical, INC. | $34.46 | 2025 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $27.10 | 2025 | Rexulti |
| Aytu Biopharma, INC. | $25.87 | 2020-2023 | Karbinal |
| Alk-Abello, INC | $25.53 | 2024 | Ragwitek, Grastek, Odactra |
| Supernus Pharmaceuticals, INC. | $25.11 | 2022-2024 | Qelbree |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $17.06 | 2025 | Xelstrym |
| Ultragenyx Pharmaceutical INC. | $15.99 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.99 | 2019 | |
| Sarepta Therapeutics, INC. | $14.12 | 2022 | |
| Organon LLC | $14.01 | 2025 | |
| Sanofi Pasteur INC. | $12.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Entwistle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.